Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease leading to death within a few years of diagnosis despite medical therapy. On the basis of methodologies of the Cochrane collaboration, this overview discusses the evidence for IPF therapy. Good-quality studies on oral corticosteroids, the most common medical therapy in use for IPF, are lacking. A few small studies have been carried out on the efficacy of many non-steroid immunosuppressive agents, and the results have been generally disappointing. The most extensively studied medical therapy, gamma interferon, showed a significant effect in a small randomized study, but its efficacy was not confirmed in a larger randomized-controlled trial. The long-awaited good news for patients affected by this deadly disease, and for their physicians, could come in the near future from large randomized-controlled trials with gamma interferon or other immunomodulatory agents.

Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis / F., Luppi; Cerri, Stefania; Beghe', Bianca; Fabbri, Leonardo; Richeldi, Luca. - In: RESPIRATORY MEDICINE. - ISSN 0954-6111. - STAMPA. - 98:(2004), pp. 1035-1044.

Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis

CERRI, Stefania;BEGHE', Bianca;FABBRI, Leonardo;RICHELDI, Luca
2004-01-01

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease leading to death within a few years of diagnosis despite medical therapy. On the basis of methodologies of the Cochrane collaboration, this overview discusses the evidence for IPF therapy. Good-quality studies on oral corticosteroids, the most common medical therapy in use for IPF, are lacking. A few small studies have been carried out on the efficacy of many non-steroid immunosuppressive agents, and the results have been generally disappointing. The most extensively studied medical therapy, gamma interferon, showed a significant effect in a small randomized study, but its efficacy was not confirmed in a larger randomized-controlled trial. The long-awaited good news for patients affected by this deadly disease, and for their physicians, could come in the near future from large randomized-controlled trials with gamma interferon or other immunomodulatory agents.
98
1035
1044
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis / F., Luppi; Cerri, Stefania; Beghe', Bianca; Fabbri, Leonardo; Richeldi, Luca. - In: RESPIRATORY MEDICINE. - ISSN 0954-6111. - STAMPA. - 98:(2004), pp. 1035-1044.
F., Luppi; Cerri, Stefania; Beghe', Bianca; Fabbri, Leonardo; Richeldi, Luca
File in questo prodotto:
File Dimensione Formato  
Resp Med_ steroids_2004.pdf

Accesso riservato

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 221.72 kB
Formato Adobe PDF
221.72 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/613039
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 31
social impact